FEELM
14.5.2023 17:06:34 CEST | Business Wire | Press release
FEELM launched its new innovative disposable vape solution FEELM Max, at the Vaper Expo UK 2023 in Birmingham on May 13.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230514005039/en/
Johnny Zhang, The Assistant President at FEELM (Photo: Business Wire)
As a leading vaping technology provider and flagship brand of atomization tech company SMOORE, FEELM unveiled the advanced FEELM Max solution which boasts three major breakthroughs: the advanced heating technology of the Ceramic Coil S1, a constant power control system and mindful design.
With the first products featuring the FEELM Max solution about to launch in the UK and EU markets, the launch was attended by many top level representatives from many client companies including BAT, RELX International, Totally Wicked, and KIWI.
Setting New 800-Puff Benchmark for 2 ML E-Liquid
The coil technology journey began with first-generation cotton wick coils, progressed to second-generation cotton mesh coil, and has now developed into the era of third-generation ceramic coil technology with the FEELM Max being the latest manifestation of this industry innovation.
Designed to deliver a superior vaping experience, the innovative FEELM Ceramic Coil S1 brings cutting-edge coil technology that offers an increased puff count, setting a new benchmark in the market.
Benefitting from its cotton-free design and the resulting improvement of e-liquid utilization, the FEELM Max is able to boost puff count by more than 30% compared to cotton coil disposable solutions, providing 800 more puffs and setting a new benchmark for 2ml. This innovation allows products using the FEELM Ceramic Coil S1 to offer increased puff counts while remaining totally compliant with all local regulations.
In addition, the new S1 coil decreases the amount of impurities from the heating process by 78%, resulting in fresher breath and no unpleasant aftertaste. This is a significant stride towards ensuring a clean and silky vaping experience for consumers.
Electronic and Design Breakthroughs
The FEELM Max solution uses a constant power energy management system for stable vaping and over 95% vapor consistency. This technology improves taste consistency by 35%, which further enhances the user experience.
FEELM Max products showcase a transparent e-liquid tank for both aesthetics and user convenience. No longer will vapers have to guess how much e-liquid is left in their device because one quick look will let them know. The CMF Lab refines this design through specialized research and has developed a scientific ergonomic model for the vaping industry.
First Industrial End-To-End Whole-Chain Recycling Scheme
FEELM has also launched the first industrial whole-chain recycling scheme, collaborating with RELX International in the UK. Conscious of the potential harm of vapes ending up in landfills, FEELM has taken the responsibility for implementing a scheme that will facilitate vape recycling to a fuller extent, thereby minimising the environmental impact.
The company's commitment to making recycling more accessible demonstrates its dedication to environmental sustainability. As the initiative gains traction, it could serve as a model for other industries looking to implement eco-friendly practices and engage adult customers in sustainability efforts.
Shaping a Sustainable and Compliant Future with Partners
FEELM's success is not solely due to its innovative technology and the relentless pursuit of excellence, but also the strong collaboration it has forged with its clients and industry partners.
Bing Du, the CEO and founder of RELX International stated at the event: “Thanks to the groundbreaking technology of FEELM Max, and driven by our legendary partnership with FEELM, RELX International is on course to revolutionize the vaping experience across the globe.”
Liam Cagliarini, UK CEO of KIWI Vapor, the leading Italian brand, stated: "We aim to collaborate with FEELM on latest technology, and provide a consistency vaping experience for consumers."
Marcus Saxton, CEO of Totally Wicked, top British brand, added: "FEELM’s innovative technology has enhanced the consumer experience. As a partner of FEELM, Totally Wicked shares the responsibility of promoting sustainability in the atomization industry through active participation in the recycling system."
FEELM intends to continue pushing the boundaries of what's possible in vaping technology, while keeping its commitment to sustainability and compliance at the heart of its operations. The company's mission to shape a better vaping industry, not only for today but for generations to come, remains stronger than ever.
About FEELM
As a flagship tech brand belonging to SMOORE, FEELM is the world’s leading closed vape system solution provider. Based on the world's leading Ceramic Coil Heating Technology, FEELM combines authentic Flavor Reproduction Technology with innovative electronics technology, bringing ultimate sensation and premium vaping experience.
About SMOORE
Founded in 2009, SMOORE is a global leader in atomization technology solutions, covering reduced-risk products, medical, pharmaceutical, and beauty atomization technologies. With inter-disciplinary atomization research and a diverse product portfolio, SMOORE is committed to becoming an advanced platform, aspired to make life better.
With continuous R&D investment and leading manufacturing capacity, SMOORE has 14 technology research centers worldwide and products are available in more than 50 countries and regions. SMOORE announced IPO in Hong Kong on July 10, 2020.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230514005039/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom